Recently, Xavier Nogués from the Autonomous University of Barcelona Department of Medicine and other prominent Spanish academic medical centers recently reported on the latest Vitamin D study of hospitalized COVID-19 patients. Out of Barcelona, Spain, the investigators look to evaluate the effect of calcifediol treatment on ICU admission and mortality in hospitalized COVID-19 patients in Spain. Based on these results, it appears to be a randomized prospective study of 930 patients. Out of those patients, the majority was randomly assigned to calcifediol treatment at 532 ug day 1 and 266 ug days 3,7,15 and 30 at the time of admission. 379 patients were used as controls. The net result of this study, according to the Spanish investigators: patients hospitalized with COVID-19 given calcifediol treatment at the time of hospitalization significantly reduced ICU admission and mortality.
The study of this study involved 930 patients, 551 of whom were randomly assigned to calcifediol treatment at 532 ug day 1 and 266 ug days 3,7,15 and 30 at time of admission. While 379 patients were treated as controls the results revealed that 30 (5.4%) of the patients treated with calcifediol required ICU as compared to 80 out of 379 controls (21.1%; p<0.0001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, gender, linearized 25 (OH) D levels at baseline, and comorbidities showed that treated patients experienced a reduction in risk to require ICU (RR 0.18 [95% Cl 0.11;0.29]). Baseline 25(OH) D levels inversely correlated with the risk of ICU admission (RR 0.53[95% CI 0.35; 0.80]).
Overall mortality was 10%. Based on an Intention-to-treat analysis, 36% (6.5%) out of 551 patients treated with calcifediol at admission died compared to 57 patients (15%) out of 379 controls (p=0.001). Adjusted results showed a reduced mortality to more than 60%. Higher baseline 25(OH)D levels were significantly associated with decreased mortality (RR 0.40[95% Cl 0.24;0.67]).
The study authors interpret these findings as significant—treating these patients with calcifediol at the time of hospitalization materially reduces ICU admission and mortality.
Xavier Nogués, Autonomous University of Barcelona Department of Medicine
For other authors, please follow the link.